In a story from Multiple Sclerosis News Today, multiple sclerosis is known for its variability- one patient's experience may look nothing like a friend's with the same disease. For this…
As reported in GSK, the FDA has just granted priority review to Nucala (mepolizumab), a targeted biological treatment to help patients with hypereosinophilic syndrome (HES). If the medication is accepted,…
Many myasthenia gravis patients do not benefit from already existing therapies, such as steroids, acetylcholinesterase inhibitors, or immunosuppressants. It is this fact that has pushed many biotechnology companies to start…
Daily use of Nuplazid (pimavanserin) leads to strong and sustained reductions in the frequency and severity of hallucinations and delusions in people with Parkinson’s disease psychosis, according to data from…
According to BioSpace, biotechnology company Argenx recently announced positive results from their Phase III ADAPT clinical trial. The company, who seeks to find breakthroughs in immunology and translate them…
Over the last few months, most of the news you've read has been about COVID-19. Though the first cases appeared in November or December of 2019, the novel coronavirus…
According to a drug filing and press release from Pharmaceutical Business Review, the FDA granted a priority review to GlaxoSmithKline for their humanized monoclonal antibody therapy, Nucala (mepolizumab). Currently,…
My coworker isn't social distancing. In fact, she's more touchy than ever. She always wants to cuddle or play when I'm in the middle of writing an article. She yells…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
